Nilanjana (Nilu) Rana
About Nilanjana (Nilu) Rana
Nilanjana (Nilu) Rana is the Vice President of Drug Safety & Pharmacovigilance at Alkermes, with over 20 years of experience in the field.
Current Role at Alkermes
Nilanjana (Nilu) Rana currently serves as the Vice President of Drug Safety & Pharmacovigilance at Alkermes in Waltham, Massachusetts, United States. In this role, she is responsible for overseeing drug safety operations and ensuring the efficacy and safety of pharmaceutical products. Her extensive experience in pharmacovigilance and drug safety management positions her as a key leader within the organization.
Past Experience at Sage Therapeutics
Nilanjana Rana worked at Sage Therapeutics from 2020 to 2023, first as the Senior Medical Director of Drug Safety and Pharmacovigilance, and then as the Executive Medical Director in the same department. Based in Cambridge, Massachusetts, she was responsible for leading the drug safety initiatives, ensuring compliance with regulatory standards, and contributing to various drug development projects.
Leadership Role at Amgen
From 2017 to 2020, Nilanjana served as the Global Safety Officer and Biosimilars Safety Team Lead at Amgen in Thousand Oaks, California. During her tenure, she led the global safety team for biosimilars and played a pivotal role in the development and safety monitoring of these products. Her contributions were essential in maintaining safety protocols and ensuring regulatory compliance for biosimilar drugs.
Experience at Sanofi Genzyme
Nilanjana Rana was employed by Sanofi Genzyme as the Senior Director of Global Pharmacovigilance & Epidemiology from 2015 to 2016. In this role, she was involved in global pharmacovigilance and epidemiology efforts, ensuring the safety and efficacy of Sanofi Genzyme's pharmaceutical products. She brought her extensive knowledge and expertise to the table, contributing significantly to the organization's drug safety protocols.
Educational Background
Nilanjana holds a medical degree (M.B.B.S.) from Lady Hardinge Medical College. She further extended her education by studying Clinical Trials Design and Management at the University of California, Santa Cruz Extension. Her academic background provides a solid foundation for her extensive career in drug safety and pharmacovigilance.